Navigation auf


Institute for Regenerative Medicine • IREM

Old News (Archive)

News list

  • Generali M. et al.: "Heterogeneous Expression of ACE2 and TMPRRS2 in Mesenchymal Stromal Cells" in Journal of Cellular and Molecular Medicine

  • IREM at Science Agora

    From Earth to Space to Earth: From Regenerative Medicine to Biodiversity – Science from Switzerland

  • iPSC Core Facility at IREM

    The Institute for Regenerative Medicine, which has the mission to advance molecular life sciences into next generation therapies, established recently the iPSC Core Facility to promote this powerful technology at the UZH and other institutions.

  • New publication by Melanie Generali in Journal Genes

    New insights into the biology of an aggressive pediatric cancer, which will help focus future research goals.

  • IREM to participate at Scientifica

  • Prof Martin Schwab will give this year's "Wings For Life" Lecture

    "From the bench to clinical trials for a regeneration enhancing anti-Nogo-A antibody therapy for spinal cord injury"

  • FDA approval of Aducanumab for the treatment of Alzheimer’s disease

    The Institute for Regenerative Medicine (IREM) is pleased to share the news that the U.S. Food and Drug Administration (FDA) has approved aducanumab for the treatment of Alzheimer’s disease. Alzheimer’s disease is the most common form of dementia and accounts for 50-75% of all cases worldwide.

  • Ruslan Rust receives 3RCC Grant for "Experimental toolkit to evaluate cell-based therapies in the mouse brain"

  • New Minor in BioMedEntrepreneurship

  • Dr. Ramona Weber receives a HFSP postdoctoral long-term fellowship

  • URPP Kick-off Event 23 March 2021

  • New IREM seminar series Innovations in Regenerative Medicine

  • New Publication by Ruslan Rust in Journal of Cerebral Blood Flow and Metabolism

  • Harnessing cell therapies to fight COVID-19: Basic research, clinical evidence and patient access

  • BrainFair 15. - 19.März 2021

  • 2nd IREM Scientific Art Photo Competition 2021

  • Ruslan Rust receives SNF Spark Grant to develop a brain-shuttle for cell therapies

  • Nature - Scientific Reports publication by M. Y. Emmert/ S. Motta and E. Fioretta (first authors)

    "Geometry influences inflammatory host cell response and remodeling in tissue-engineered heart valves in-vivo”

  • Spark grant 2020-2021 awarded to Sarah Motta

    “Rethinking multi-organ tissue-engineering: an in-vitro model to design regenerative native-like tissue-engineered heart valves”

  • New Publication by Rebecca Weber and Ruslan Rust in Frontiers in Physiology

    "Characterization of the Blood Brain Barrier Disruption in the Photothrombotic Stroke Model"

  • Visiting Professor Sandra Loerakker

    We welcome Professor Sandra Loerakker as a Visiting Professor at our institute.

  • New publication in Nature Reviews Cardiology by M.Y. Emmert and colleagues

  • Distinct changes in all major components of the neurovascular unit across different neuropathological stages of Alzheimer's disease

  • New University Research Priority Programs (URPP) ITINERARE

    In order to underpin its position among the world’s leading research institutions, the University of Zurich has established its University Research Priority Programs (URPP). The URPP create and promote academic networks in selected areas of research and contribute to the advancement of knowledge in areas of research that benefit society.

  • Kyoto University and the University of Zurich have officially established a strategic partnership

  • Human Cardiac Organoids for Modeling Genetic Cardiomyopathy

    New paper by Michele Filippo Buono, Lisa von Boehmer, Jaan Strang, Simon P. Hoerstrup, Maximilian Y. Emmert and Bramasta Nugraha, published on 20 July

  • New Minor in BioMed Entrepreneurship at IREM

  • Therapeutic antibodies targeting CNS : Comparative Study by Correa et al. of intrathecal, intravenous, and subcutaneous anti-Nogo A antibody treatment after stroke in rats

    Anna S Wahl, Daphne Correa on ‘Targeting Therapeutic Antibodies to the CNS: A Comparative Study of Intrathecal, Intravenous, and Subcutaneous Anti-Nogo A Antibody Treatment after Stroke in Rats’, published in Neurotherapeutics

  • Wrona et al.: CRISPR-Directed Therapeutic Correction at the NCF1 Locus Is Challenged by Frequent Incidence of Chromosomal Deletions

  • Two of our IREM scientists – Debora Kehl and Ruslan Rust – have been selected to participate on the 70th Nobel Laureate Meeting

    Once every year, around 30-40 Nobel Laureates and 600 excellent, young scientists from all around the world convene in Lindau, to foster the exchange among scientists of different generations, cultures and disciplines. This year’s 70th Nobel Laureate Meeting is an interdisciplinary meeting, where scientists from all three natural sciences – chemistry, physic and medicine – are united.

  • Ruslan Rust et al. in Frontiers in Neuroscience: A Practical Guide to the Automated Analysis of Vascular Growth, Maturation and Injury in the Brain

  • IREM Organization Update

  • Ruslan Rust et al. in JCBFM: "Insights Into the Dual Role of Angiogenesis Following Stroke"

    Stroke remains a major cause of serious disability due to the brain’s limited capacity to regenerate.

  • New publication of Fioretta et al. in JACC: Basic to Translational Science.

  • Prof. Dr. Janine Reichenbach new associate professor for Somatic Gene Therapy

    Prof. Dr. Janine Reichenbach has started as associate professor for Somatic Gene Therapy at the Institute for Regenerative Medicine (IREM), chairing this new division of the institute.

  • IREM Professor Janine Reichenbach is member of the new HMZ flagship project Immuno-TargET.

    Autoimmune diseases and cancer have highly interesting parallels that can be used for novel therapeutic approaches. Tumours that originate from endocrine (hormone-producing) organs such as the thyroid gland, the parathyroid gland, the pituitary gland or the gastrointestinal tract are often characterised by excessive hormone production and frequently retain the functional and molecular properties of their originating organ.

  • IREM Professor Max Emmert receives Techno-College Innovation Award

    IREM Professor Max Emmert received the Techno-College Innovation Award for the LifeMatrix, a human cell derived acellular engineered tissue platform.

  • Fixing Hearts, Saving Lives

  • Rust et al: Anti-Nogo-A antibodies prevent vascular leakage and act as pro-angiogenic factors following stroke.

    In this study, we demonstrate that antibody-mediated Nogo-A neutralization following stroke has strong pro-angiogenic effects but does not increase vascular permeability as opposed to the Vascular Endothelial Growth Factor (VEGF). Moreover, VEGF-induced vascular permeability was partially prevented when VEGF was co-administered with anti-Nogo-A antibodies. This study may provide a novel therapeutic strategy for vascular repair and maturation in the ischemic brain.

  • Unconventional research and novel scientific approaches: Two Spark grants awarded to IREM researchers

    In July 2019, the SNSF launched the funding scheme Spark as a pilot project to support unconventional research and novel scientific approa­ches. Each application was evaluated in a double-blind procedure by two members of an international pool of experts. It was the idea that counted most of all. Other important criteria were the quality of the submitted pro­ject proposal and the potential impact of the results.

  • First iPSC lecture will take place at the University of Zurich

    We are delighted to announce that the first iPSC lecture will take place at the University of Zurich. This lecture series will provide a forum to disseminate state-of-the-art iPSC research, build relationships with one-another, renew and establish collaborations and strategies. Experts in the field of iPSC technology will share their knowledge.

  • New analysis of study results showed clinical benefit of Aducanumab

    October 23, 2019 -- IREM is pleased to learn that Biogen plans regulatory filing for aducanumab in Alzheimer's disease based on a new analysis of a larger data set from Phase 3 studies. Neurimmune, a spin-out company of the University of Zurich, discovered aducanumab together with a research group at the University of Zurich that went on to co-found IREM. In 2007 Neurimmune and Biogen entered into a collaborative development and license agreement for aducanumab's development and commercialization.

  • UZH IncubatorLab: Mit Era-107 den Appetit sanft bändigen

    Viele Schlankheitsmittel sind gesundheitsschädlich oder zu wenig wirksam. Nun entwickelt ein Startup der UZH einen Appetithemmer, der keine unerwünschten Nebenwirkungen hervorruft und das Gewicht im Vergleich zu zugelassenen Standardmedikamenten im Tiermodell doppelt so stark reduziert.

  • ISACB+ISVTE conference abstracts published

    The International Symposium for Applied Cardiovascular Biology and Vascular Tissue Engineering (ISACB+ISVTE) has successfully come to an end.

  • ERC Starting Grant awarded to Prof. Maximilian Emmert

  • S. Motta et al.: Human cell-derived tissue-engineered heart valve with integrated Valsalva sinuses: towards native-like transcatheter pulmonary valve replacements; new publication in npj Regenerative Medicine - Nature.

  • Autologous endothelialized small-caliber vascular grafts engineered from blood-derived induced pluripotent stem cells

  • Rust et al: Review on Therapeutic Angiogenesis in «Trends in Neurosciences»

  • Sherida de Leeuw and Christian Tackenberg, “Alzheimer’s in a dish – Induced pluripotent stem cell-based disease modeling”, published in Translational Neurodegeneration

  • Frank Baaijens, Rektor TU Eindhoven and Visiting Professor IREM: Die TU Eindhoven stellt nur noch Frauen ein.

  • Rust et al: New Therapy Promotes Vascular Repair Following Stroke

    Following a stroke, antibodies that inhibit the signaling molecule Nogo-A can help repair blood vessels in the affected brain regions. This also promotes the regaining of motor functions, researchers at the University of Zurich have shown in a mouse model. The study opens up new avenues for treatment.


  • Debora Kehl et al. in "Nature Regenerative Medicine"

    “Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential" by Kehl et al. was published in Nature Regenerative Medicine

  • Janine Reichenbach in UZH magazine

  • Visiting Professor Frank Baaijens

    We welcome Professor Frank Baaijens as a Visiting Professor at our institute.

  • Annual meeting 2019 of medAlumni UZH took place at IREM

    medAlumni, an organization of alumni of the medical faculty of UZH had their annual meeting at our institute.

    This year's topic was "Regenerative Medizin in der Forschung und die unternehmerische Umsetzung".

  • RESTORE (with IREM participation) is one of the winners of a pan-European competition addressing grand scientific and technological challenges that could change our future.

  • Review about iPSC microglia in “Stem Cells”

  • Article in «Tages-Anzeiger» from 25 Jan 2019 portrays the Wyss Zurich Lab at Moussonstrasse and their Co-Director Simon P. Hoerstrup.

  • Cover Story and Cover Picture on "Science Translational Medicine"

  • Neuroscience Center Zurich Membership for Dr. Christian Tackenberg

    IREM scientist accepted as full member and group leader

  • Certificate of Excellence for Dr. Katrin Rauen

    IREM scientist awarded for clinical research

  • Sex differences in Alzheimer disease ‒ the gateway to precision medicine: Article in "Nature Reviews Neurology"

    Alzheimer disease (AD) is characterized by wide heterogeneity in cognit­ive and behavioural syndromes, risk factors and patho­physio­logical mechanisms. Addressing this phenotypic variation will be crucial for the development of precise and effective therapeutics in AD.

  • RESTORE successfully passed the first round of the FET Flagship competition and is preparing for the next phase

    On 18 May, the European Commission (EC) announced that the FET Flagship RESTORE, which was initiated by the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), has been selected to enter the next phase of the FET Flagship competition. A successful FET Flagship will eventually receive around EUR 1 billion for ten years by the EC (9th research framework program) and other sponsors to enable groundbreaking research projects. The research initiative RESTORE has been selected as one of five proposals in the field of "Health and Life Sciences" and is now working with stakeholders to refine its extended concept for the second selection round later this year.

  • Computer-designed heart valves implanted into sheep for the first time

    Using computer simulations, researchers developed heart valves that regenerate and grow with the body.

  • UZH Start-Up Funding for Young Innovators

    In addition to its core responsibilities in research and teaching, the University of Zurich provides targeted funding for innovative projects. With its new BioEntrepreneur Fellowships, UZH supports junior researchers in adapting scholarly findings and technologies for commercial use. And thanks to a generous donation, UZH is now able to expand the program.

  • Vom Computer massgeschneiderte regenerative Herzklappen

    Herzfehler behandeln mit Prothesen, die wachsen und sich regenerieren – das ist das Ziel des kardiovaskulären Tissue Engineering. Gemeinsam haben nun Forschende der Universität Zürich, der Technischen Universität Eindhoven und der Charité Berlin zum ersten Mal erfolgreich regenerative Herzklappen bei Schafen eingesetzt, die mithilfe von Computersimulationen designt wurden.

  • IREM Director Prof. Simon Hoerstrup meets Dr. Craig Venter (J.Craig Venter Institute and Human Longevity Inc., La Jolla, California

  • Award-Winning Medical Research

    This year's winners of the Pfizer Research Awards include seven researchers from the University of Zurich and the University's hospitals.

  • Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) today announced results from a recently conducted analysis of the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for early Alzheimer’s disease.

  • Standort Zürich hat Trümpfe für Biotechnologie in der Hand

    Zürich - Der Grossraum Zürich hat diejenigen Trümpfe, die es für einen erfolgreichen Biotechnologie-Standort benötigt, sagt Roger Nitsch, Präsident des Schlieremer Unternehmens Neurimmune. Er hat die guten Köpfe und die Infrastruktur, darunter gerade auch den Bio-Technopark Schlieren-Zürich.

  • IREM research project awarded with UZH Forschungskredit

  • IREM in Boston

    At the end of May, the executive board and UZH researchers spent two days in Boston. The trip was designed to foster relationships and build new cooperation arrangements with Harvard University, the Massachusetts Institute of Technology (MIT), and other institutions in the Greater Boston Area.

  • Engineering heart valves for the many

    Harvard’s Wyss Institute and the University of Zurich partner to create a next-generation heart valve that accurately functions upon implantation and regenerates into long-lasting heart-like tissue

  • Stammzellenforschung: Mitwachsende Prothesen für Babyherzen

    (19.04.2017, Neue Zürcher Zeitung) Künstliche Herzklappen wachsen nicht. Um wiederholte Eingriffe bei Kindern zu vermeiden, haben Forscher einen wachsenden Herzklappenersatz entwickelt. Nach 20 Jahren Forschung stehen sie vor ersten Tests im Mensch.

  • Article "The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease" among top 100 most-discussed journal articles of 2016 Foreign Policy magazine recognizes Prof. R. Nitsch as one of the "Top 100 Global Thinkers 2016"

    Article "The antibody aducanumab reduces Aß plaques in Alzheimer's disease" among top 100 most discussed journal articles of 2016

    Foreign Policy Magazine recognizes Prof. R. Nitsch as one of the "Top 100 Global Thinkers 2016"

  • Antibody Aducanumab Reduces Brain Amyloid Plaques in Alzheimer's Patients

    Aducanumab, an antibody developed by the University of Zurich, has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer's disease. These protein deposits in the brain are a classic sign of Alzheimer's disease and contribute to the progressive degeneration of brain cells. The researchers furthermore demonstrated in an early stage clinical study that, after one year of treatment with Aducanumab, cognitive decline could be significantly slowed in antibody-treated patients as opposed to the placebo group.

  • The Aino University in Osaka, Japan, conferred on the IREM Director Prof. Roger M. Nitsch the title of distinction "Overseas Visiting Professor of Health Science". In honor of outstanding performance and dedication in the field of education and research of health science.

  • Royal Society of Medicine London, UK: Living engineered matrices to regenerate the heart (LifeMatrix); Interview with Professor Sir Magdi Yacoub and Professor Simon P. Hoerstrup / Royal Society of Medicine London, GB: Lebende Matrices zur Wiederherstellung des Herzens (LifeMatrix); Interview mit Professor Sir Magdi Yacoub und Professor Simon P. Hoerstrup


  • 3D-printer in medicine - bio-ink for organs / 3D-Drucker in der Medizin - Bio-Tinte für neue Organe

    Using tissue engineering different roads can lead towards the same goal. One of these is the 3D printer, which can be used printing structures such as noses and ears. / Bei der Gewebezüchtung führen verschiedene Wege zum Ziel. Einer davon ist der 3D-Drucker, mit dem bereits einfache Gewebe wie Nasen und Ohren ausgedruckt werden können.

    Zum Artikel

  • Zurich meets London: From Russell Square to Oxford Circus / Zürich trifft London: Vom Russel Square zum Oxford Circus

    The LifeMatrix project (tissue-engineered human matrix technology for the treatment of children with congenital heart disease) has been presented by the Wyss Zurich towards leading experts from Imperial College London. Challenges of the clinical translation in regenerative medicine at the Royal Society of Medicine has been discussed. / Das LifeMatrix Projekt (Künstlich hergestellte menschliche Gewebematrix für die Behandlung von Kindern mit angeborenen Herzerkrankungen) wurde von Vertretern des Wyss Zürich gegenüber führenden Experten vom Imperial College London vorgestellt. Dabei wurden Herausforderungen der klinischen Translation in der regenerativen Medizin an der "Royal Society of Medicine" diskutiert.

    Read more

  • At the "Dies academicus 2016 " at the University of Zurich Prof. Dr. Maximilian Emmert was awarded by the science prize of Walter and Gertrud Siegenthaler Foundation / Am "Dies academicus 2016" der Universität Zürich wurde der Wissenschaftspreis der Walter und Gertrud Siegenthaler Stiftung an Prof. Dr. Maximilian Emmert vergeben

    Prof. Emmert receives science award in recognition of his scientific and clinical activity in the field of cardiovascular regenerative medicine. Main research interests are the tissue engineering of heart valves with growth and regeneration potential and the cardiac stem cell therapy. Mr. Emmert is next to his clinical work at the University Hospital research group leader at the Institute for Regenerative Medicine ( ) and Co - Director of the Life Matrix project at Wyss Translational Center Zurich ( / Prof. Emmert erhält den Wissenschaftspreis in Anerkennung seiner wissenschaftlichen und klinischen Tätigkeit im Bereich der kardiovaskulären Regenerativen Medizin. Hauptforschungsschwerpunkte sind das Tissue engineering von Herzklappen mit Wachstums- und Regenerationspotenzial sowie die kardiale Stammzelltherapie. Herr Emmert ist neben seiner klinischen Tätigkeit am Universitätsspital Forschungsgruppenleiter am Institut für Regenerative Medizin ( und Co-Leiter des LifeMatrix Projektes am Wyss Translational Center Zürich (

  • Start of Clinical Study with Aducanumab / Start einer klinischen Studie zu Aducanumab

  • Roger Nitsch honored at Alzheimer's translation and therapeutic panel and luncheon by the American Federation for Aging Research (AFAR)

  • ETH and University of Zurich found Wyss Translational Center Zurich / ETH und Universität Zürich gründen Wyss Translational Center Zurich

    ETH Zurich and the University of Zurich found a new translational research center at the interface of medicine, science and engineering. / Die ETH Zürich und die Universität Zürich gründen ein neues translationales Forschungszentrum an der Schnittstelle von Medizin, Natur- und Ingenieurwissenschaften.

  • Swiss researchers transplanted first artificial skin / Schweizer Forscher verpflanzen erstmals Kunsthaut

  • Growing heart valves - spare valves for the heart with regeneration potential / Mitwachsende Herzklappen - Regenerationsfähige Ersatzventile für das Herz

    Defective heart valves can now be easily replaced. However, in children and young adults implants show several limitations. One solution is expected from tissue engineering. / Defekte Herzklappen lassen sich heute problemlos austauschen. Doch bei Kindern und jungen Erwachsenen stossen die Implantate an Grenzen. Einen Ausweg erhofft man sich von der Gewebezucht.

  • The University of Zurich and the Wyss Institute at Harvard University start partnership / Die Universität Zürich und das Wyss Institute der Harvard University gehen Partnerschaft ein

    The Wyss Institute at Harvard University and the University of Zurich announced today the signing of a cooperation agreement / Das Wyss Institute der Harvard University und die Universität Zürich geben heute die Unterzeichnung eines Kooperationsvertrages bekannt.

  • From our own breeding / Aus eigener Zucht

  • Researchers are working on heart valves for babies / Forscher arbeiten an Herzklappen für Babys

    At the Swiss Center for Regenerative Medicine researchers are working on heart valves for babies. Such an innovation could improve the quality of life of many children. The bred heart valve could replace the artificial valve. / Im Schweizer Zentrum für Regenerative Medizin wird an einer Herzklappe für Babys gearbeitet. Eine solche Neuerung könnte die Lebensqualität vieler Kinder verbessern. Die gezüchtete könnte die künstliche Klappe ablösen.

  • Cell- and Tissue Biobank (CTBB) membership "Gemeinschaft Deutscher Kryobanken e.V."

  • Tissue for heart repair / Gewebe für Herzreparatur

    A team fro Zurich tests bred cell clumps on pigs / Zürcher Team testet gezüchtete Zellklumpen an Schweinen.

  • It will be possible to recreate organs in the laboratory / Es wird möglich sein, Organe im Labor nachzubauen

    For the first time human stem cells have been successfully cloned. Biologist Sebastian Jessberger reports about replacement organs on the bench, personalized medicine and ethical concerns. / Erstmals in der Geschichte wurden menschliche Stammzellen erfolgreich geklont. Biologe Sebastian Jessberger über Ersatzorgane auf dem Labortisch, individuelle Medizin und ethische Bedenken.

  • Artificial skin for burn victims / Künstliche Haut für Brandopfer

  • The science in the footsteps of Prometheus / Die Wissenschaft auf den Spuren von Prometheus

  • Researchers from Zurich grow skin for children with burns / Zürcher Forscher züchten Haut für Kinder mit Verbrennungen

  • Vein replacement from their own stem cells / Venen-Ersatz aus den eigenen Stammzellen

    Doctors have a child transplanted a vein, which they previously have been bred from stem cells. This and other examples show that tissue engineering works in the bloodstream. / Ärzte haben einem Kind eine Vene transplantiert, die sie aus Stammzellen züchteten. Dieses und weitere Beispiele zeigen, dass Tissue-Engineering im Blutkreislauf funktioniert.

  • With tissue engineering against tissue and organ damage / Mit Tissue Engineering gegen Gewebe- und Organschäden

    Why does future medicine focus on regenerative tissue engineering? / Weshalb setzt die Zukunftsmedizin auf die regenerative Gewebezüchtung?

  • Organs out of the bioreactor / Organe aus dem Bioreaktor

  • 9.9 million euros for the research project "Life VALVE" at the University of Zurich and the University Hospital Zurich / 9.9 Millionen Euro für das Forschungsprojekt „LifeVALVE” an der Universität und am UniversitätsSpital Zürich

    Under the 7th Framework Program (FP7-HEALTH-2009-single-stage), the Commission of the European Union has authorized the official launch of the project "Life VALVE" up from 1 November 2009. This is the third substantial promotion of the research program "Regenerative Medicine" at the University Hospital Zurich and the University of Zurich in the current year. / Im Rahmen des 7. Framework Program (FP7-HEALTH-2009-single-stage) hat die Kommission der Europäischen Union den offiziellen Start des Forschungsprojektes „Life VALVE” zum 1. November 2009 autorisiert. Es ist dies die dritte substantielle Förderung des Forschungsschwerpunktes „Regenerative Medizin“ am Universitäts-Spital Zürich und an der Universität Zürich im laufenden Jahr.